Genetic predictors of response to antidepressants in the GENDEP project.
The objective of the Genome-based Therapeutic Drugs for Depression study is to investigate the function of variations in genes encoding key proteins in serotonin, norepinephrine, neurotrophic and glucocorticoid signaling in determining the response to serotonin-reuptake-inhibiting and norepinephrine-reuptake-inhibiting antidepressants. A total of 116 single nucleotide polymorphisms in 10 candidate genes were genotyped in 760 adult patients with moderate-to-severe depression, treated with escitalopram (a serotonin reuptake inhibitor) or nortriptyline (a norepinephrine reuptake inhibitor) for 12 weeks in an open-label part-randomized multicenter study. The effect of genetic variants on change in depressive symptoms was evaluated using mixed linear models. Several variants in a serotonin receptor gene (HTR2A) predicted response to escitalopram with one marker (rs9316233) explaining 1.1% of variance (P=0.0016). Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants. Two HTR2A markers remained significant after hypothesis-wide correction for multiple testing. A false discovery rate of 0.106 for the three strongest associations indicated that the multiple findings are unlikely to be false positives. The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encoding proteins in norepinephrine signaling influencing response to the norepinephrine-reuptake-inhibiting nortriptyline and a common pathway gene influencing response to both antidepressants. The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction.
Uher
Rudolf
R
MRC Social Genetic and Developmental Psychiatry Center, Institute of Psychiatry, King's College London, London, UK. r.uher@iop.kcl.ac.uk
Huezo-Diaz
Patricia
P
Perroud
Nader
N
Smith
Rebecca
R
Rietschel
Marcella
M
Mors
Ole
O
Hauser
Joanna
J
Maier
Wolfgang
W
Kozel
Dejan
D
Henigsberg
Neven
N
Barreto
Mara
M
Placentino
Anna
A
Dernovsek
Mojca Zvezdana
MZ
Schulze
Thomas G
TG
Kalember
Petra
P
Zobel
Astrid
A
Czerski
Piotr M
PM
Larsen
Erik Roj
ER
Souery
Daniel
D
Giovannini
Caterina
C
Gray
Joanna M
JM
Lewis
Cathryn M
CM
Farmer
Anne
A
Aitchison
Katherine J
KJ
McGuffin
Peter
P
Craig
Ian
I
D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D015283:Citalopram / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000235:genetics*; D006801:Humans; D015810:Linkage Disequilibrium; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000187:drug effects / Q000235:genetics*; D009661:Nortriptyline / Q000627:therapeutic use; D010597:Pharmacogenetics / Q000379:methods*; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects / Q000235:genetics*; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000235:genetics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D000928:Antidepressive Agents; D015283:Citalopram; D050484:Norepinephrine Plasma Membrane Transport Proteins; D009661:Nortriptyline; D044402:Receptor, Serotonin, 5-HT2A; D011965:Receptors, Glucocorticoid; D017367:Selective Serotonin Reuptake Inhibitors; C497713:NR3C1 protein, human; C493227:SLC6A2 protein, human